The first line of defense operates at the parasite membrane. By mutating, deleting, or amplifying transporters, parasites can keep intracellular drug concentrations below toxic thresholds even when patients receive correctly dosed regimens. In Plasmodium falciparum, the digestive-vacuole transporter PfCRT exports protonated chloroquine away from its site of action, undermining the drug’s interference with heme detoxification, while PfMDR1 modulates the partitioning of chloroquine, mefloquine, and artemisinin-combination partner drugs between cytosol and vacuole. Field data from Benin show that more than a decade after artemisinin-based combination therapy deployment, wild-type Pfcrt K76 alleles have re-emerged as predominant, consistent with restored chloroquine sensitivity, while Pfmdr1 N86 and Y184F variants linked to reduced lumefantrine susceptibility remain frequent in artemether-lumefantrine-treated populations. Additional ATP-binding cassette transporters such as PfMRP1, which exports glutathione conjugates and several antimalarials, add functional redundancy that makes transporter-based resistance robust.

Kinetoplastid parasites deploy an equally sophisticated transport strategy. Pentavalent antimonials must be reduced to the active trivalent form, which enters Leishmania mainly through the aquaglyceroporin AQP1; resistant isolates commonly show reduced AQP1 expression, inactivating mutations, or gene deletions. Simultaneously, the ABC transporter MRPA, amplified on episomes or through chromosome 23 polysomy, sequesters antimony-trypanothione conjugates into intracellular vesicles, a mechanism strongly associated with high-grade antimonial resistance on the Indian subcontinent. Miltefosine resistance follows a parallel route centered on the LdMT/LdRos3 flippase complex, where point mutations, truncations, and subtelomeric deletions can reduce drug uptake by more than 95 percent, with accompanying shifts in fatty-acid composition and ergosterol content further limiting drug partitioning into membranes. In Trypanosoma brucei, loss of the aquaglyceroporin AQP2, which imports melarsoprol and pentamidine, is the definitive driver of clinical resistance to these drugs.

The second major mechanism involves changing the molecules drugs bind to. In P. falciparum, antifolate resistance is the textbook case: stepwise accumulation of dhfr mutations N51I, C59R, and S108N together with dhps mutations such as A437G and K540E progressively reduces binding of sulfadoxine-pyrimethamine while preserving folate metabolism. Deep-sequencing surveillance in Benin has documented high frequencies of the dhfr triple mutant and the dhps A437G mutation, though the absence of K540E suggests the highest-level resistance genotypes remain rare, allowing some continued utility for intermittent preventive treatment. Artemisinin resistance adds complexity through mutations in the kelch13 propeller domain, validated by gene editing as causal drivers of reduced susceptibility, alongside pfk13-independent routes involving pfcoronin, chromosome 14 copy-number variants, and the endocytosis regulators pfap2mu and pfubp1.

Where Plasmodium relies on discrete point mutations, Leishmania exploits extreme genomic plasticity. Amphotericin B-resistant isolates remodel sterol biosynthesis, decreasing ergosterol and accumulating alternative intermediates such as cholesta-5,7,24-trien-3β-ol through mutations and copy-number changes in sterol C24-methyltransferase and C5-desaturase, thereby reducing the drug’s preferred membrane binding sites. Whole-genome sequencing of Leishmania donovani demonstrates that aneuploidy is adaptive and environment-dependent: chromosomes bearing resistance or virulence genes can become polysomic under in vitro drug selection and then revert toward disomy in the mammalian host. This reversible gene-dosage modulation provides a rapid mechanism for adjusting effective target abundance, and ribosome profiling of antimony-resistant Leishmania tropica reveals a further post-transcriptional layer, with thousands of transcripts, including those encoding trypanothione metabolism and redox enzymes, differentially loaded onto ribosomes even in the absence of drug pressure.

Metabolic reprogramming forms a third protective tier. Antimony-resistant Leishmania strains consistently elevate intracellular thiols such as trypanothione, glutathione, and cysteine, which facilitate sequestration of antimony-thiol conjugates via MRPA and enhance detoxification of reactive oxygen species. Overexpression of trypanothione pathway enzymes and tryparedoxin peroxidase strengthens antioxidant defenses. For nitroheterocyclic drugs used against trypanosomes, resistance often arises through loss or reduction of the nitroreductase enzymes required to activate the prodrugs, blurring the boundary between metabolic adaptation and target modification. In P. falciparum, resistance to compounds such as fosmidomycin and halofuginone has been linked to adaptive metabolic responses including altered proline metabolism, suggesting that metabolic rewiring acts as a background layer that lowers effective drug potency and facilitates the selection of high-level resistance alleles.

Perhaps the most clinically troubling mechanism is persistence. Subpopulations of Plasmodium, Trypanosoma, and Leishmania can enter dormant, persister-like states characterized by slowed proliferation, reduced metabolic activity, condensed chromatin, and extensive transcriptomic and translational reorganization, evading both immune clearance and chemotherapy. Brief exposure of P. falciparum to dihydroartemisinin enriches for dormant ring-stage parasites that resume proliferation days after treatment ends, a phenotype pronounced in kelch13-mutant parasites. Plasmodium vivax hypnozoites exemplify long-term dormancy, with expression signatures dominated by RNA-binding proteins and translational repressors. Emerging mechanisms extend this theme: kelch13 and pfap2mu mutations reduce hemoglobin endocytosis, lowering the free heme pool needed to activate artemisinin, while mutations in the PfCARL locus and vesicle-associated proteins threaten next-generation antimalarials such as ganaplacide by disrupting intracellular drug trafficking.

Detecting these layered defenses depends on advanced genomics. Next-generation sequencing has replaced phenotypic assays as the gold standard for surveillance, providing the depth needed to detect low-frequency resistant subclones within mixed infections before they become clinically dominant. The computational challenges are substantial: the P. falciparum genome exceeds 80 percent AT content, reaching roughly 90 percent in non-coding regions, causing PCR amplification bias and uneven coverage that demand specialized mapping algorithms. For kinetoplastids, pipelines must resolve aneuploidy, copy-number variation, and environment-dependent polysomy, and integrate ribosome-profiling data to map translational reprogramming. The authors emphasize that resistance must be embedded into the earliest stages of drug discovery rather than treated as a clinical afterthought, incorporating pharmacokinetic and pharmacodynamic modeling with transmission dynamics to predict population-level outcomes.

Looking forward, the review highlights parasite-specific targets that lack human homologues, such as calcium-dependent protein kinases in apicomplexans and parasite-derived secreted kinases in kinetoplastids, as routes to potent efficacy with minimal host toxicity. CRISPR/Cas9 gene editing, now workable even in previously intractable trypanosomatids, enables rigorous validation of candidate targets and resistance loci, while 3D bioengineered tissues, organoids, and humanized mice offer ethically sound, human-relevant alternatives to conventional rodent models. The central message is that durable antiprotozoal therapy will require compounds designed from the outset to withstand transporter redundancy, genomic flexibility, and persistence-related tolerance, combined with genomic surveillance, molecular diagnostics, and mathematical modeling to anticipate rather than merely react to the next wave of resistance.

Subject of Research: Molecular mechanisms of drug resistance in protozoan parasites including Plasmodium, Leishmania, and Trypanosoma

Article Title: Molecular mechanisms underlying drug resistance in protozoan parasites: emerging mechanisms and therapeutic perspectives

Article References: Uduwela, K., & Ranasinghe, K. (2026). Molecular mechanisms underlying drug resistance in protozoan parasites: emerging mechanisms and therapeutic perspectives. Frontiers in Parasitology, 5, Article 1934996. https://doi.org/10.3389/fpara.2026.1934996

Image Credits: AI Generated

DOI: 10.3389/fpara.2026.1934996

Keywords: drug resistance, protozoan parasites, Plasmodium falciparum, Leishmania, Trypanosoma brucei, malaria, artemisinin resistance, PfCRT, genomic plasticity, aneuploidy, parasite persistence, genomic surveillance

The research team, led by Olivia M. Shorthouse and Juan F. Quintana, set out to answer a deceptively simple question. Reproductive dysfunction has been reported anecdotally in both human patients and experimental animals infected with T. brucei, but nobody knew whether the parasites actually entered the female reproductive tract or whether the observed problems were merely secondary effects of systemic illness. By tracking parasite localisation during both acute and chronic stages of infection in mice, the investigators demonstrated that the organisms take up residence in the endometrium, the specialised mucosal lining of the uterus. This direct infiltration of reproductive tissue places the parasite in intimate contact with the immune cells and hormone-responsive epithelium that govern fertility.

What the parasites do once they arrive proved to be as important as where they settle. The study revealed a progressive and multi-layered deterioration of reproductive health as infection moved from its acute phase into chronicity. Chronically infected mice lost substantial fat mass, a sign of the metabolic wasting characteristic of trypanosome disease. Their oestrous cycles, the rodent equivalent of the menstrual cycle, became disrupted and eventually arrested. The uterus and ovaries themselves shrank, showing measurable atrophy. Perhaps most strikingly, the researchers documented extensive transcriptional dysregulation across the hypothalamic-pituitary-gonadal axis, the hormonal control circuit that links the brain to the gonads and orchestrates fertility from the top down.

The hypothalamic-pituitary-gonadal axis is a delicate three-tiered system. The hypothalamus, a small region at the base of the brain, releases gonadotropin-releasing hormone in pulses that instruct the pituitary gland to secrete luteinising hormone and follicle-stimulating hormone. These hormones, in turn, act on the ovaries to drive follicle development, ovulation, and the production of oestrogen and progesterone. The new findings show that chronic T. brucei infection distorts gene expression at every level of this hierarchy, implying that the parasite does not merely damage the uterus locally but interferes with the central neuroendocrine commands that regulate it. This systemic rewiring of reproductive control represents a form of pathology that has rarely been characterised in parasitic infection.

Immune remodelling within the uterus emerged as a central feature of the disease process. In both acute and chronic infection, the researchers observed infiltration of T cells into uterine tissue and activation of pro-inflammatory myeloid cells, the innate immune population that includes monocytes, macrophages, and their inflammatory descendants. Beyond the uterus itself, the team detected broader type 1 inflammatory signatures spreading across reproductive tissues and components of the hypothalamic-pituitary-gonadal axis. Type 1 inflammation, typically driven by interferon signalling and associated with defence against intracellular pathogens, is not normally the dominant immune tone of the reproductive tract, which tends to favour tolerance and controlled responses. Its expansion here suggests that the infection fundamentally reprograms the immunological identity of the female reproductive organs.

The ovaries told their own story of damage. Examination of ovarian pathology revealed follicular degeneration, meaning the structures that house and nurture developing eggs were deteriorating. The researchers also counted a reduction in corpora lutea, the transient endocrine structures that form after ovulation and produce the progesterone needed to support early pregnancy. Fewer corpora lutea indicate fewer successful ovulations, a direct readout of impaired fertility. Alongside these structural changes, alterations to steroidogenic pathways were detected, pointing to disruption of the enzymatic machinery that converts cholesterol into the steroid hormones essential for cyclicity and reproduction.

One of the most compelling experiments in the study involved a therapeutic intervention designed to disentangle two competing explanations. If the uterine damage were driven purely by falling oestrogen levels, then restoring oestrogen signalling should rescue the tissue. The researchers treated infected mice with tamoxifen, a selective oestrogen receptor modulator widely known for its use in breast cancer therapy. The results were revealing but partial. Tamoxifen restored uterine morphology and prevented the arrest of the oestrous cycle, demonstrating that endocrine dysfunction is indeed a major driver of the structural collapse of the uterus. However, the hormone treatment did not reverse the infection-induced remodelling of the uterine immune environment. The inflammatory cell populations and their activation states persisted despite hormonal rescue.

This dissociation carries a significant conceptual message: endocrine dysfunction and infection-driven inflammation are two distinct processes, each contributing to reproductive pathology through separate routes. Hormonal collapse explains the loss of normal uterine architecture and cyclicity, but the immune reprogramming is a direct consequence of the infection itself and cannot be corrected simply by fixing the hormonal signal. For patients, this implies that treating the hormonal consequences of chronic parasitic disease may not be sufficient to restore full reproductive health unless the underlying inflammatory drive, and ideally the infection itself, is also addressed. It also raises the possibility that immune-mediated damage to the reproductive tract could outlast or operate independently of the visible endocrine symptoms.

The broader significance of the work lies in what it says about systemic infection as a whole. The female reproductive tract is an immunologically dynamic organ that must balance defence against pathogens with the tolerance required for successful reproduction. The new findings identify it as a major target of T. brucei infection and demonstrate how a chronic parasitic disease can disrupt reproductive physiology through a combination of immune, endocrine, and metabolic pathways acting in parallel. Fat wasting, hypothalamic dysregulation, ovarian degeneration, and uterine inflammation are not isolated phenomena but interconnected consequences of a systemic infection that reaches into every tier of reproductive control. The authors suggest that this interplay between metabolism, immunity, and endocrinology may be relevant well beyond trypanosomiasis.

Indeed, the study closes with a methodological warning for the wider research community. Because the female reproductive tract has been so frequently overlooked in models of systemic inflammation, the effects of other infectious and inflammatory diseases on fertility and reproductive endocrinology may be underappreciated. The researchers argue that future studies of systemic inflammatory conditions should specifically assess the female reproductive tract rather than assuming it is a passive bystander. For sleeping sickness, a disease that affects tens of thousands of people in sub-Saharan Africa, the findings open a new dimension of clinical concern and a new set of questions about how parasitic infection shapes long-term reproductive health in survivors. They also provide a framework for investigating whether other chronic infections quietly inflict similar damage on the reproductive system.

Subject of Research: Trypanosoma brucei infection of the female reproductive tract and its effects on uterine immunity and reproductive hormone regulation

Article Title: Trypanosoma brucei infection remodels the uterine immune environment and drives neuroendocrine dysfunction

Article References: Shorthouse, O. M., Barnes, C., Colombo, S. A. P., Costa, J., Wonsbek, K., Mohon, A., MacDonald, A. S., Mann, E., Costain, A. H., & Quintana, J. F. (2026). Trypanosoma brucei infection remodels the uterine immune environment and drives neuroendocrine dysfunction. PLOS Pathogens, 22(10), e1014667. https://doi.org/10.1371/journal.ppat.1014667

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014667

Keywords: Trypanosoma brucei, sleeping sickness, uterus, endometrium, reproductive immunology, hypothalamic-pituitary-gonadal axis, oestrous cycle, ovarian pathology, tamoxifen, inflammation, parasitology, PLOS Pathogens

The study, led by Deborah Buba of the University of Jos and Ahmadu Bello University in Nigeria, together with colleagues including Peter Mac Asaga of the University Medical Centre Freiburg, compared infections caused by two major African trypanosome species, Trypanosoma congolense and Trypanosoma brucei, in BALB/c mice. These two parasites are responsible for a large share of the animal trypanosomosis burden transmitted by tsetse flies across the continent. T. congolense is notorious among veterinarians for the severe anaemia it produces in cattle, while T. brucei, a close relative of the parasites that cause human sleeping sickness, is known for its ability to invade a wide range of host tissues. Despite their clinical importance, the combined influence of parasite species, inoculation route and host immune response on disease severity had rarely been examined within a single controlled experiment.

The researchers divided the animals into four infected groups of fifteen mice each, with one group receiving T. congolense and another T. brucei by intraperitoneal inoculation, and the remaining two groups receiving the respective parasites intramuscularly. A fifth group of five uninfected mice served as controls. Over the course of the experiment, the team tracked parasitaemia, body weight, rectal temperature and survival, and at defined endpoints they measured packed cell volume, a full panel of haematological indices, serum concentrations of the cytokines interferon-gamma and interleukin-10, and semi-quantitative pathology scores for the liver, spleen and kidney. The design, approved by the Ahmadu Bello University Committee on Animal Use and Care and reported according to the ARRIVE 2.0 guidelines, applied predefined humane endpoints so that no animal was permitted to reach a moribund state.

The survival data were unambiguous. Differences between the groups were highly significant, with a log-rank test yielding a p value below 0.0001. Mice infected intraperitoneally with T. congolense had the shortest median survival of any group, at just nine days. At the other extreme, mice infected intramuscularly with T. brucei survived longest among the infected groups. The two intermediate groups, intramuscular T. congolense and intraperitoneal T. brucei, fell between these poles. What makes this pattern remarkable is what the parasitaemia data did not show: the time until parasites became detectable in the blood and the peak levels they reached were broadly comparable across the infected groups. In other words, the animals that died fastest were not carrying the heaviest parasite burdens, a discordance that strikes at the heart of how virulence is conventionally assessed in laboratory models of trypanosomosis.

Haematological findings reinforced the clinical picture of acute disease. Infected animals developed anaemia, reflected in reduced packed cell volume, along with thrombocytopenia, a depletion of blood platelets. Both changes are hallmarks of African trypanosomosis in livestock and have been linked in previous work to the destruction or removal of red blood cells driven by inflammatory activation of the mononuclear phagocyte system. Earlier studies have implicated interferon-gamma produced by natural killer cells, natural killer T cells and CD8-positive T cells in driving myeloid cell activation and erythrophagocytosis, the engulfment of red blood cells by macrophages, which culminates in the acute anaemia characteristic of these infections. Other mechanisms, including the desialylation of red blood cells by parasite enzymes and cytokine-mediated haemodilution, have been proposed to contribute to the anaemia seen with different trypanosome species.

The cytokine measurements added a layer of nuance. Interferon-gamma, a pro-inflammatory signalling molecule central to the activation of macrophages during protozoal infections, was elevated in all infected animals relative to uninfected controls. However, its concentrations did not distinguish among the four infected groups, meaning this canonical inflammatory signal was similarly engaged regardless of parasite species or inoculation route. Interleukin-10, an anti-inflammatory cytokine that restrains excessive immune activation, told a different story. Its concentrations were higher in mice infected with T. congolense than in those infected with T. brucei, a species-associated pattern that suggests the two parasites elicit qualitatively different immunoregulatory environments within the same inbred host strain.

The histopathological analysis was equally revealing, both for what it showed and for what it did not. Semi-quantitative scoring of the liver, spleen and kidney confirmed that infection inflicted significant damage on all three organs: pathology scores were significantly higher in infected animals than in uninfected controls. Yet when the infected groups were compared with one another, the scores did not differ significantly. The severity of organ-level lesions, like the parasite burden, failed to track with survival. Mice that succumbed rapidly to intraperitoneal T. congolense infection did not carry measurably worse tissue damage than mice that survived longer with T. brucei. This second discordance, between lesion severity and outcome, implies that the functional consequences of infection, rather than the visible structural damage, may be what determines how quickly an animal deteriorates.

Taken together, the results paint a picture in which disease outcome in African trypanosomosis is governed by something more subtle than parasite load or tissue destruction. The authors suggest that species-associated host responses may contribute to disease outcome, although they are careful to note that further mechanistic investigation is required before the causal pathways can be pinned down. One plausible interpretation is that the balance between pro-inflammatory and anti-inflammatory signalling, exemplified here by the species-linked differences in interleukin-10, shapes the physiological toll of infection independently of how many parasites are present or how damaged the organs appear. Excessive or poorly regulated inflammation could accelerate clinical decline even when parasite numbers and histological lesions are comparable, a concept consistent with the broader literature on immunopathology in trypanosome infections.

The findings also carry practical implications for experimental design in trypanosomosis research. Laboratory models of animal African trypanosomosis have long been criticised for their reliance on syringe-passaged parasites and laboratory rodents, which can diverge from the natural tsetse-transmitted infections seen in clinically relevant livestock hosts. The demonstration that inoculation route measurably alters survival, with intramuscular delivery of T. brucei producing the most prolonged course, echoes earlier work showing that route of inoculation influences the virulence of both T. congolense and T. brucei brucei in mice. Researchers selecting a challenge model should therefore be aware that the route of infection is not a neutral variable but an active determinant of disease tempo, one that could confound comparisons between studies or mask genuine differences in parasite virulence or drug efficacy.

For the veterinary and medical communities, the study underscores a message that has been building across the trypanosomosis literature: virulence is a property of the interaction between parasite and host, not of the parasite alone. Recent work has revealed that African trypanosomes occupy unexpected tissue niches, including the skin and adipose tissue, where they may persist and adapt in ways that influence transmission and disease. The new data add a controlled, quantitative demonstration that two closely related parasite species, delivered at comparable infectious doses into the same host strain, can produce the same parasite burden and the same organ pathology while killing at different speeds and provoking different cytokine profiles. Untangling the mechanisms behind these discordances, particularly the role of interleukin-10 and other immunoregulatory pathways, may ultimately inform approaches that target the damaging host response as well as the parasite itself, an increasingly recognised strategy for diseases in which immunopathology drives the clinical picture.

Subject of Research: Comparative pathogenicity and multi-organ histopathology of Trypanosoma congolense and Trypanosoma brucei infection in mice

Article Title: Comparative Pathogenicity and Semi-quantitative Multi-organ Histopathology of Trypanosoma congolense and Trypanosoma brucei Infection in Mice

Article References: Buba, D., Adamu, S., Mohammed, B., Jatau, I. D., & Asaga, P. M. (2026). Comparative Pathogenicity and Semi-quantitative Multi-organ Histopathology of Trypanosoma congolense and Trypanosoma brucei Infection in Mice. Acta Parasitologica, 71(5), Article 232. https://doi.org/10.1007/s11686-026-01417-8

Image Credits: AI Generated

DOI: 10.1007/s11686-026-01417-8

Keywords: Trypanosoma congolense, Trypanosoma brucei, animal African trypanosomosis, pathogenicity, inoculation route, anaemia, histopathology, cytokines, IFN-gamma, IL-10, murine model, parasitaemia

T. brucei leads a double life, cycling between the bloodstream of mammals and the gut of the tsetse fly. Within the mammalian host, the parasite exists mainly in two forms: the long slender form, which divides rapidly and drives parasitaemia upward, and the short stumpy form, a non-dividing stage produced through a quorum-sensing mechanism once parasite density climbs. The stumpy form is the parasite’s ticket to the next stage of its life cycle, primed to differentiate into procyclic forms once it reaches the fly. Yet stumpy cells are also fragile. Earlier work showed they survive only around four days in the bloodstream, and during the remission of the first parasitaemic peak in mice they disappear far faster than their natural turnover alone could explain. Something else, the researchers suspected, was accelerating their demise.

The team’s first clue came from body temperature. In C57BL/6J mice infected with pleomorphic T. brucei, parasitaemia first became detectable around three days post-infection, and by day four the slender forms had begun differentiating into stumpy cells just as fever set in. Both parasite load and body temperature peaked on days four and five, when stumpy forms made up nearly three-quarters of the population. Parasitaemia then collapsed to undetectable levels by day seven, coinciding with the return of body temperature to baseline. A Pearson correlation analysis confirmed a strong positive relationship between parasitaemia and temperature during the first week of infection, with a correlation coefficient of 0.678. A multiple linear regression model, which explained 67.54 percent of the variance in late-phase parasite levels, singled out the temperature window spanning days three to five as a significant predictor of subsequent parasite decline.

To test whether heat itself could kill stumpy cells, the researchers purified them from infected mice and cultured them at different temperatures. At 27 degrees Celsius, the temperature of the tsetse fly, the cells survived and even began differentiating into procyclic forms. At 37 degrees, normal mammalian body temperature, they underwent their expected natural turnover over roughly three to four days. But at 39 degrees, a fever temperature previously recorded in infected mice, mortality climbed steeply. Notably, long slender forms tolerated prolonged heat exposure far better; only the stumpy cells declined sharply within the first 48 hours. Fever, the results suggest, places a disproportionate burden on the very stage of the parasite that is already winding down.

The interplay with antibodies proved equally revealing. Plasma from mice at 21 days post-infection, rich in effective antibodies, suppressed stumpy cells in culture but could not eliminate them completely, unlike its effect on slender forms. Plasma from mice at day six, when the first peak collapses, showed no killing activity against either form. Yet when elevated temperature and day-21 plasma were combined, more than 99.5 percent of stumpy cells were eradicated within 24 hours, while either treatment alone left 15 to 18 percent alive. This synergy indicates that the well-documented IgM and complement-mediated clearance of the first parasitaemic peak is only part of the story. The parasite’s own heat sensitivity, amplified by fever, appears to be an underappreciated partner in that dramatic remission.

What happens inside a heat-stressed stumpy cell? The researchers found that apoptosis-like events, detected through phosphatidylserine exposure, rose from almost nothing at 27 degrees to 3.72 percent after 24 hours at 37 degrees and 30.63 percent at 39 degrees. Slender forms showed essentially no such events at any temperature. Gene expression analysis pointed to the mitochondrion as the driver: Metacasp-3, a mitochondrial-associated apoptosis gene, was upregulated roughly twofold at 37 degrees. Fluorescence imaging of mitochondria stained with MitoTracker revealed progressive damage, with punctate dye aggregation appearing in about 43 percent of cells after 24 hours at 37 degrees and over 95 percent after the same period at 39 degrees. Transmission electron microscopy confirmed the structural toll, showing fenestrated mitochondrial membranes and multivesicular structures suggestive of a stress-induced degradative pathway resembling autophagy.

Mitochondrial dysfunction went hand in hand with oxidative stress. Using MitoSOX staining, the team measured mitochondrial reactive oxygen species accumulating in stumpy cells exposed to heat: 15.30 percent of cells showed oxidative stress after 24 hours at 37 degrees, rising to 44.58 percent at 39 degrees, while cells kept at 27 degrees remained largely unaffected. The reactive oxygen species co-localized with the damaged mitochondria, reinforcing the link between heat, mitochondrial injury, and cell death. Mitochondrial membrane potential, a key indicator of mitochondrial health, collapsed in parallel, falling to 51.36 percent of baseline at 37 degrees and just 19.38 percent at 39 degrees. Slender forms, by contrast, showed neither mitochondrial oxidative stress nor membrane potential loss under the same conditions.

Untargeted metabolomics added a metabolic dimension to the picture. Comparing stumpy cells incubated for 12 hours at 37 versus 39 degrees, the researchers detected 306 significantly altered metabolites among more than 22,000 measured. The most striking change was a sixfold accumulation of succinate at fever temperature, alongside elevated glucose-6-phosphate and 3-phosphoglycerate, pointing to disrupted energy production through glycolysis and the TCA cycle. The team attributes the succinate surge to mitochondrial fumarate reductase, an enzyme known to generate reactive oxygen species and highly expressed in stumpy cells. Lipid metabolism was also disturbed: myristic acid, a key component of the parasite’s surface GPI anchors, accumulated at 39 degrees, while carnitine, needed for fatty acid degradation, dropped significantly, suggesting the cells could neither properly remodel nor dispose of their lipids under febrile stress.

The findings carry broader implications for how trypanosome infections unfold. Stumpy cells lack complexes III and IV of the electron transport chain and maintain their membrane potential through glycolysis-derived ATP and a reversed ATP synthase, a precarious arrangement the authors describe as dancing on a knife-edge. This metabolic mismatch between a partially activated TCA cycle and a limited antioxidant arsenal, including lower levels of iron superoxide dismutase than in slender forms, may be an evolutionary trade-off that pre-adapts the parasite for the insect gut at the cost of vulnerability to mammalian fever. It may also explain why trypanosomes take refuge in the cooler, peripheral tissues of the skin and adipose tissue, and why livestock species with naturally higher baseline body temperatures often show low parasitaemia yet remain reservoirs for transmission.

The authors caution that they were unable to create a fever-suppressed mouse model to prove causation directly, though earlier veterinary studies found that anti-inflammatory drugs raised parasitaemia in infected animals, indirectly supporting the fever-clearance hypothesis. They also note that natural infections initiated by tsetse bites produce lower first peaks than experimental injections, so fever’s role there may be more modest, though still relevant before specific antibodies appear. Because fever is among the most common clinical signs in human patients, and because stumpy cells resist antibody-mediated elimination better than slender forms do, the study proposes that temperature-driven clearance complements immunity throughout infection. Understanding the molecular basis of this thermo-sensitivity, the researchers conclude, could open new avenues for controlling a disease that still threatens millions across sub-Saharan Africa.

Subject of Research: Heat-induced degeneration of short stumpy Trypanosoma brucei forms and the role of fever in clearing the first parasitaemic peak

Article Title: Thermo-related degeneration of stumpy forms of Trypanosoma brucei, the pathogen of African sleeping sickness

Article References: Thermo-related degeneration of stumpy forms of Trypanosoma brucei, the pathogen of African sleeping sickness. (n.d.). https://doi.org/10.1007/s44307-025-00081-9

Image Credits: AI Generated

DOI: 10.1007/s44307-025-00081-9

Keywords: Trypanosoma brucei, sleeping sickness, short stumpy form, fever, mitochondrial damage, oxidative stress, apoptosis-like cell death, metabolomics, glycolysis, TCA cycle, parasitaemia, tsetse fly

Trypanosomatid flagellates such as Trypanosoma brucei and T. cruzi have long fascinated cell biologists because their endocytic traffic is confined to a single invagination of the plasma membrane called the flagellar pocket. This unusual geometry makes them powerful models for testing how universal the principles of membrane trafficking really are. Previous work had catalogued many components of clathrin-mediated endocytosis in these parasites, but the composition and evolutionary standing of their ESCRT machinery remained incompletely resolved. In animals and fungi, a subcomplex called ESCRT-0, built around the Vps27/Hrs and STAM proteins, recognises ubiquitylated substrates and hands them to the downstream complexes. Whether trypanosomes possess anything comparable has been an open question.

The team approached the problem from two directions: comparative genomics across the eukaryotic tree and experimental biochemistry in the parasite itself. Using hidden Markov model searches and reciprocal best BLAST analyses, they surveyed hundreds of genomes from every major eukaryotic supergroup for orthologs of candidate sorting proteins. In parallel, they engineered procyclic-form T. brucei cells to express an endogenous GFP-tagged version of Vps23, the Tsg101 orthologue that anchors the ESCRT-I complex. Affinity purification followed by quantitative mass spectrometry then pulled down the proteins that travel with TbVps23 in living cells, allowing the researchers to confirm predicted partners and uncover unexpected ones.

The most striking biochemical discovery was that trypanosome ESCRT-I is not the canonical heterotetramer familiar from yeast and animals. Instead, the purification identified two novel Vps23-interacting proteins, encoded by adjacent open reading frames Tb927.11.2020 and Tb927.11.2030, that travel stoichiometrically with the core subunits. These proteins are specific to trypanosomes, with no obvious homologues outside the kinetoplastid lineage, and their association with Vps23 indicates that the trypanosome ESCRT-I subcomplex is a heteropentamer. The finding adds a new tier of compositional divergence to a complex long considered structurally conserved, and it underscores how evolutionary flexibility can be woven into even the most fundamental cellular machines.

Equally consequential is the team’s answer to the question of what serves as the trypanosome ESCRT-0 analogue. Rather than a Vps27/STAM pair, which the analyses confirmed is absent from most non-opisthokont lineages, the parasites employ Tom1, a protein carrying the VHS and GAT domains that is broadly distributed across eukaryotes. The researchers demonstrated that trypanosome Tom1, termed TbTom1, colocalises with TbVps23 at endosomal membranes and interacts with a kinetoplastid-specific partner protein the authors nicknamed Jerry, a multi-domain protein studded with three FYVE domains, lipid-binding modules that recognise endosomal phosphoinositides. Together, Tom1 and Jerry appear to fulfil the substrate-recognition role that ESCRT-0 plays in fungi and animals, but through entirely different molecular parts.

Structural predictions reinforced the ancient pedigree of this arrangement. AlphaFold3 modelling of TbTom1 revealed a compact, well-ordered VHS helical bundle linked to a GAT domain, closely superimposable on the VHS domain of human TOM-1, while the remaining regions of the protein are predicted to be intrinsically disordered. This architecture supports the authors’ proposal that Tom1 is the ancestral VHS-GAT-domain-containing cargo adaptor, present in the last common ancestor of eukaryotes and retained across supergroups, whereas the Vps27/Hrs-STAM system of ESCRT-0 is a later innovation restricted to animals and fungi. By mapping the occurrence of Tom1 and Jerry orthologues across the Euglenozoa, the researchers showed that Tom1 is universally retained within the phylum while Jerry is absent from diplonemids, tracing a lineage-specific layer of specialisation on top of a conserved core.

The experimental evidence connecting these proteins to endocytic function came from cellular phenotyping. Cells expressing tagged versions of TbTom1 or TbJerry showed significantly enlarged flagellar pockets, with morphometric analysis of DAPI-stained cells revealing a marked increase in pocket area compared with the parental line, and tagged TbJerry cells additionally displaying a subtle nozzle-like distortion of the pocket. Because the flagellar pocket is the sole site of endocytosis in trypanosomes, such expansion implies a direct perturbation of membrane uptake and trafficking throughput. The phenotypes were measured across individual cloned lines and validated by immunoblotting of endogenous tags, giving the morphological data a firm molecular footing.

Curiously, the machinery appears dispensable for parasite viability in laboratory culture. RNA interference targeting TbTom1 in bloodstream-form cells reduced transcript levels by roughly 65 percent yet left proliferation unimpaired over an eight-day course, and mass spectrometric profiling of the silenced proteome showed that overall protein composition shifted only modestly. Concanavalin A uptake assays, which track soluble cargo from the flagellar pocket through endosomes to the lysosome, proceeded indistinguishably in TbTom1-depleted cells and controls. The authors interpret this resilience as evidence of redundancy or adaptability within the trypanosome sorting network rather than irrelevance of Tom1, a pattern consistent with the plasticity that their comparative analyses document throughout the system.

Broadly, the study reframes how biologists should think about the early ESCRT machinery. Evidence that Tom1 functions within the ESCRT pathway of trypanosomes supplies the fourth eukaryotic supergroup in which such a role has been demonstrated, and the authors argue that Tom1, not Vps27/STAM, is likely part of the pan-eukaryotic early ESCRT apparatus. At the same time, the heteropentameric ESCRT-I complex and the kinetoplastid-restricted Jerry protein illustrate how individual lineages continue to elaborate and customise the machinery, echoing earlier discoveries such as the plant-specific FREE1 adaptor, whose orthologues the team also surveyed across embryophytes. Evolution, in this view, has conserved the skeleton of the sorting system while repeatedly rebuilding its sensory apparatus.

For parasitologists, the implications extend toward intervention. Trypanosomes depend on relentless endocytic turnover of their variant surface glycoproteins and invariant surface receptors to evade the immune system, and any component that is parasite-specific, such as the novel ESCRT-I subunits or Jerry, represents a potential Achilles heel that host proteins do not share. Conversely, the conserved Tom1-dependent pathway offers a benchmark against which the animal and fungal systems can be reinterpreted, potentially correcting an animal-centric bias that has coloured membrane trafficking research for decades. What this study makes clear is that the deepest lessons about how eukaryotic cells move their membranes may come not from yeast or human tissue culture, but from an ancient parasite whose cellular geography forces every molecular handoff to happen in one remarkable pocket of membrane.

Subject of Research: The composition and evolution of the ESCRT endosomal sorting system in trypanosome parasites

Article Title: The trypanosome ESCRT system possesses both novel components and under-recognised pan-eukaryotic features

Article References: Padilla-Mejia, N. E., Durante, I. M., Záhonová, K., Stříbrná, E., Heller, J., Dacks, J. B., Lukeš, J., & Field, M. C. (2026). The trypanosome ESCRT system possesses both novel components and under-recognised pan-eukaryotic features. BMC Biology. https://doi.org/10.1186/s12915-026-02730-4

Image Credits: AI Generated

DOI: 10.1186/s12915-026-02730-4

Keywords: ESCRT, endocytosis, trypanosomes, Trypanosoma brucei, Tom1, Vps23, flagellar pocket, protein trafficking, endosomes, eukaryotic evolution, VHS domain, FYVE domain

The burden of sleeping sickness is considerable. The disease progresses in stages, beginning with fever, headaches and lymphadenopathy as parasites multiply in the blood and lymph, and advancing to neurological involvement once the parasites cross the blood-brain barrier, producing sleep disturbances, cognitive decline and, if untreated, death. The parasite’s most formidable weapon is antigenic variation: a dense coat of variant surface glycoproteins, or VSGs, that is continually reshuffled through gene conversion, allowing the parasite to stay one step ahead of the host antibody response. This immune evasion strategy, well documented in the literature, has long frustrated conventional vaccine development, which is one reason the researchers turned to conserved, functionally essential proteins as alternative targets.

Specifically, the team selected three T. brucei proteins as the basis for their construct: the variant surface glycoprotein itself, heat shock protein 70, and the vacuolar transporter chaperone complex. Heat shock protein 70 is a highly conserved molecular chaperone central to protein folding and stress responses, while the vacuolar transporter chaperone complex is involved in polyphosphate synthesis and acidocalcisome function, processes essential to parasite survival. By mining these proteins for immunogenic peptides, the researchers aimed to build a construct that combines surface exposure with conservation across strains, increasing the likelihood that an immune response raised against the vaccine would recognize the parasite before it can establish infection.

The design workflow followed the now-standard logic of reverse vaccinology. Protein sequences were retrieved from the UniProt database and aligned with tools such as Clustal Omega to assess conservation. Cytotoxic T lymphocyte epitopes were predicted for MHC class I presentation, and helper T lymphocyte epitopes for MHC class II, using the Immune Epitope Database analysis resource and related servers. B-cell epitopes were predicted with linear and discontinuous methods, including ElliPro for structure-based antibody epitope mapping. Each candidate epitope was then filtered for allergenicity with AllerTOP, for toxicity with dedicated peptide toxicity predictors, and for antigenicity with VaxiJen, ensuring that only immunogenic, non-allergenic and non-toxic peptides entered the final construct.

Population coverage analysis, which estimates how many people worldwide carry HLA alleles capable of presenting the chosen epitopes, returned a striking result: the vaccine candidate achieved 100 percent global population coverage. This metric matters because a vaccine that only fits a narrow slice of HLA diversity would leave large populations unprotected. Biophysical characterization of the final multi-epitope protein showed an aliphatic index of 71.23, indicating good thermal stability, and a GRAVY score of minus 0.719, indicating a hydrophilic, soluble protein likely to fold and express well. Solubility and instability assessments supported the view that the construct should behave as a stable, expressible protein in a cellular context.

Structural modeling came next. The tertiary structure of the vaccine construct was predicted and evaluated with a TM-score of 0.65 plus or minus 0.13 and a C-score of minus 0.50, values consistent with a reliable fold. The model was then refined, and validation metrics confirmed its quality: a Ramachandran score of 86.8 percent, meaning the vast majority of residues occupy favored or allowed backbone conformations, and a ProSA Z-score of minus 5.26, within the range expected for proteins of comparable size. Disulfide engineering was considered to further stabilize the fold, and secondary structure predictions from PSIPRED and SOPMA were used to cross-check the modeled architecture.

To test whether the vaccine could actually engage the innate immune sensors that trigger adaptive responses, the team docked the construct against Toll-like receptors 2 and 4, key pattern-recognition receptors on antigen-presenting cells. Molecular docking predicted strong binding, with energy scores of minus 1013.5 kJ/mol for TLR-2 and minus 1002.8 kJ/mol for TLR-4. These docked complexes were then subjected to molecular dynamics simulation, principal component analysis, dynamic cross-correlation matrix analysis and MM-GBSA binding free energy calculations, all of which supported the stability and favorable energetics of the receptor-vaccine interactions. In practical terms, the simulations suggest the vaccine construct should bind robustly to the very receptors that initiate the innate immune cascade.

Immune simulation provided the most direct readout of the construct’s potential immunogenicity. Using computational immune system modeling, the researchers predicted robust humoral and cell-mediated responses, including elevated B lymphocyte and T lymphocyte populations and rising titers of IgM and IgG antibodies over the simulated immunization course. Cytokine profiles indicated activation of both Th1-type and Th2-type pathways, the dual signature generally desired in a prophylactic vaccine. While such simulations are approximations of a vastly more complex biological reality, they serve as a critical screening step, allowing weak candidates to be discarded before any laboratory resource is spent.

Because the platform is mRNA, the team also optimized the nucleic acid sequence itself. Codon optimization for expression in Escherichia coli strain K12, conducted for in-silico cloning into the pET-28a(+) vector, yielded a codon adaptation index of 0.9688 and a GC content of 44.70 percent, both indicative of high expression potential. In-silico cloning confirmed that the construct could be inserted into the vector without disrupting restriction sites. Finally, minimum free energy analysis of the mRNA sequence was used to evaluate the structural integrity and stability of the transcript, an important consideration since mRNA secondary structure influences translation efficiency and vaccine performance.

The authors are careful to frame the work as a computational proof of concept rather than a finished vaccine. As they conclude, the in-silico designed candidate demonstrated strong structural stability, favorable receptor interactions and promising immunogenic potential against T. brucei, but experimental validation and in-vivo studies are required to verify its safety and efficacy. That caveat applies to the entire field of computational vaccinology: docking scores and immune simulations can prioritize candidates and dramatically shorten development timelines, but only animal studies and clinical trials can establish whether a designed construct protects against real infection. Still, for a disease with no licensed vaccine, in which drug therapy is costly, logistically difficult and increasingly challenged by resistance, a rationally designed mRNA candidate that clears every computational hurdle represents a meaningful step forward, and a template for applying the same pipeline to other neglected tropical parasites.

Subject of Research: Computational immunoinformatics design of an mRNA vaccine candidate against the sleeping sickness parasite Trypanosoma brucei

Article Title: Immunoinformatics Approach for the Designing of a Novel mRNA Vaccine Candidate Against Trypanosoma brucei

Article References: Nil, M. S., Khandker, S., Sadaf, S., Ahmed, N., Reja, S., Sayfullah, M., Ferdous, J., Saha, S., Alamri, A., Khan, M. S., Ahmed, S., Wajed, S., Mahdeen, A. A., & Siddiquee, N. H. (2026). Immunoinformatics Approach for the Designing of a Novel mRNA Vaccine Candidate Against Trypanosoma brucei. Acta Parasitologica, 71(5), Article 205. https://doi.org/10.1007/s11686-026-01388-w

Image Credits: AI Generated

DOI: 10.1007/s11686-026-01388-w

Keywords: Trypanosoma brucei, human African trypanosomiasis, mRNA vaccine, immunoinformatics, reverse vaccinology, epitope prediction, molecular docking, molecular dynamics simulation, TLR-2, TLR-4, codon optimization, neglected tropical disease